April 16,MedincellAnnounced a strategic collaboration and licensing agreement with AbbVie to develop a new generation of long-acting injectable therapies. The two parties will jointly develop up to six Long-Acting Injectables (LAI) across multiple therapeutic areas and indications, with AbbVie leading the commercialization.
According to the terms of the agreement, Medincell will receive an upfront payment of $35 million and is eligible for up to $1.9 billion in development and commercial milestones ($315 million per project). Medincell is also eligible to receive mid-single-digit to low-double-digit royalties on net sales.Medincell will leverage its commercially staged, long-acting injectable technology platform to formulate innovative therapies. Medincell will carry out formulation activities and preclinical studies, including supportive CMC work, to advance the candidate drug into clinical trials. AbbVie will fund and conduct the clinical development for each project and be responsible for regulatory approval, manufacturing, and commercialization.
In April 2023, the FDA approvedTevaCo-developed with MedinCellRisperidoneSustained-Release Injectable SuspensionUzedyThis is also the first subcutaneous long-acting formulation of risperidone, administered once every one to two months. It utilizes MedinCell's proprietary BEPO technology, which enables the controlled and stable release of risperidone. Therapeutic blood concentration can be reached within 6 to 24 hours after a single dose.According to MedinCell, its patented BEPO technology can control and ensure the regular administration of drugs at optimal therapeutic doses over several days, weeks, or months. Upon injection, the BEPO technology forms a polymer deposit just a few millimeters under the skin, exerting systemic or localized targeted effects. The deposit diffuses the active ingredient through absorption over the required period, functioning like an injectable and bioresorbable micropump.Medincell CEO Christophe Douat said, "Collaborating with one of the most innovative and successful pharmaceutical companies will be an exciting partnership. Following the FDA approval of our first product in April 2023, Medincell has entered a new phase of development. The full potential of long-acting injectable therapies is increasingly being recognized."Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message to the WeChat Official Account backstage or send a message, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and cannot be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
↑ Long press to scan the QR code and sign up for the event ↑
